AI-generated research brief — verify at source
Therapeutic Apheresis Shows No Significant Standalone Benefit for Rheumatoid Arthritis in Meta-Analysis
A meta-analysis of 8 randomized controlled trials found no statistically significant improvement in functional disability, inflammation, or acute-phase reactants when therapeutic apheresis was used as a standalone treatment for rheumatoid arthritis — with pooled estimates for HAQ (SMD -1.02, 95% CI -2.15 to 0.11), ESR (SMD -0.90, 95% CI -2.41 to 0.62), and CRP (SMD -0.75, 95% CI -1.73 to 0.24) all crossing the null. The direction of the pooled effects is consistently neutral, and wide confidence intervals across all three outcomes indicate substantial imprecision in the available evidence.
What Was Studied
This review asked whether therapeutic apheresis — in any of its forms — produces measurable clinical or biochemical benefit in patients with rheumatoid arthritis, including those with refractory disease who have not responded adequately to drug-based therapies. The primary outcomes examined were patient-reported functional disability via the Health Assessment Questionnaire (HAQ), and inflammatory markers including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).
How It Was Studied
This was a systematic review and meta-analysis drawing on studies retrieved from PubMed, Web of Science, and the Cochrane Library, with a search cutoff of December 12, 2024. Eligible studies included randomized controlled trials and case series enrolling at least five patients with rheumatoid arthritis who received any type of therapeutic apheresis. In total, 16 studies were included — 10 RCTs and 6 case series — with the quantitative meta-analysis restricted to 8 of the RCTs that included appropriate control comparators. Methodological quality was evaluated using the Cochrane Risk of Bias 2 (ROB2) tool for RCTs and the Joanna Briggs Institute (JBI) checklist for case series, and the overall certainty of evidence was graded using the GRADE framework. A random-effects model was applied to account for anticipated variability across studies.
What Was Observed
- Functional disability (HAQ): The pooled effect of apheresis on patient-reported functional status trended toward improvement but did not reach statistical significance — the confidence interval just crossed zero (SMD -1.02, 95% CI -2.15 to 0.11). This means the data are consistent with either a modest benefit or no benefit at all.
- Erythrocyte sedimentation rate (ESR): No statistically significant reduction in this inflammatory marker was observed across trials (SMD -0.90, 95% CI -2.41 to 0.62). The very wide confidence interval signals a high degree of uncertainty and variability between studies.
- C-reactive protein (CRP): Similarly, the pooled effect on CRP did not reach significance (SMD -0.75, 95% CI -1.73 to 0.24), with the estimate again spanning both possible benefit and no effect. Substantial heterogeneity was noted across all three outcome domains.
Why This Matters
Rheumatoid arthritis remains uncontrolled in a meaningful proportion of patients despite advances in pharmacological treatment, and therapeutic apheresis has been explored as an alternative in refractory cases. However, clinical evidence on this approach has until now been dispersed and largely confined to early studies. This systematic review provides the first quantitative synthesis of that evidence base, and its neutral findings challenge the premise that apheresis offers meaningful standalone benefit — while simultaneously highlighting that the evidence is too limited and heterogeneous to draw definitive conclusions.
How to Read This Result
Given the medium quality of the underlying evidence, substantial between-study heterogeneity, reliance on predominantly early and methodologically variable trials, and GRADE-assessed uncertainty across all outcomes, these pooled estimates should be interpreted with considerable caution and do not support firm conclusions about the role of therapeutic apheresis in rheumatoid arthritis management.
Limitations
Substantial heterogeneity was observed across all pooled outcomes, undermining confidence in the summary estimates. The evidence base is largely drawn from early studies with scattered clinical data, and methodological variability across included trials was identified through ROB2 and JBI quality assessments. The GRADE framework indicated low certainty of evidence overall. The inclusion of case series alongside RCTs, and the restriction of the meta-analysis to only 8 of the 10 RCTs, further constrains the interpretability of the findings.